Crispr Therapeutics shares tumble after significant earnings miss
Steven Madden , Ltd. (NASDAQ:SHOO) shares have tumbled to a 52-week low, touching down at $28.51, as the fashion-forward footwear and accessories brand faces headwinds in a challenging retail environment. According to InvestingPro data, the stock’s RSI suggests oversold conditions, while the company maintains solid fundamentals with a "Good" financial health score and a healthy 2.9% dividend yield. This latest price level reflects a significant retreat from previous market positions, with the company’s stock experiencing a stark 1-year change, plummeting by -31.47%. While nine analysts have revised their earnings downwards for the upcoming period, the company maintains strong fundamentals with more cash than debt and a current ratio of 2.16. Investors and analysts are closely monitoring Steven Madden’s performance as the company navigates through the shifting landscapes of consumer demand and global supply chain issues. Discover more valuable insights about SHOO and 1,400+ other stocks with an InvestingPro subscription, including comprehensive Fair Value analysis and expert research reports.
In other recent news, Steven Madden reported its fourth-quarter 2024 earnings, exceeding expectations with an earnings per share (EPS) of $0.55 and revenue of $582.3 million, surpassing the anticipated $550.64 million. The company demonstrated strong financial health throughout 2024, with a 15.2% increase in full-year revenue, reaching $2.3 billion, and a net income of $192.4 million. Looking ahead, Steven Madden projects a 17-19% revenue increase for 2025, driven in part by the strategic acquisition of British retailer Kurt Geiger, which is expected to close in the second quarter of 2025. This acquisition is anticipated to be accretive to earnings, although the company’s EPS forecast for 2025 falls short of consensus estimates due to potential tariff impacts.
Analysts have adjusted their outlooks on Steven Madden, with Telsey Advisory Group lowering its price target to $38, maintaining a Market Perform rating, and Jefferies reducing its target to $36 while keeping a Hold rating. Both firms noted pressure on gross margins and highlighted the challenges posed by potential tariff re-implementations. Despite these concerns, Steven Madden’s revenue guidance for 2025, which includes the Kurt Geiger acquisition, is notably above prior consensus estimates. The company’s performance in international markets, accessories, and direct-to-consumer segments has shown progress, although profitability remains a concern amid an uncertain macroeconomic environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.